Statement by Pakistan at the 24th Session of the Standing Committee on the Law of Patents (SCP), Geneva 27-30 June 2016
We are happy to see you chairing this meeting. We also appreciate the work of the Secretariat in preparing for the session.
The SCP is an important committee especially with implications for many sectors particularly public health, technology transfer and patent-related flexibilities. It is unfortunate that we could not agree to a program of work at the last session. It is important that deliberations here are inclusive and cognizant of differences in the social, economic and technological development of Member States, as well as the TRIPS flexibilities, respect for intellectual property laws and the needs of all Members.
We note the compilation of Member States’ experience and case studies on the effectiveness of Exceptions and Limitations, particularly in addressing development issues contained in document SCP 23/3. We again request the Secretariat to update the study and invite submissions from a broader audience including civil society organizations, research institutions, and local industries in developing countries about their practical experiences on this matter.
Emergence of new diseases and epidemics pose a global health threat challenging both developed and developing countries. The basic human right to health is denied to increasingly large populations globally because they cannot afford treatment. The revised WHO Model List of Essential Medicines includes new medicines for treating hepatitis C, cancer and drug-resistant tuberculosis most of which are unaffordable to a large population.
Pakistan supports the African Group/ DAG proposal contained in document SCP/16/7 and SCP/16/7 CORR. The SCP is the appropriate forum for sharing experiences on the use of health related patent flexibilities and the challenges to their use. There is a need to analyze specific challenges to availability of medicines arising from the patent system in developing countries and LDCs, facilitator impact if any of the patent system on innovation of medicines for diseases predominantly prevalent in developing countries and whether the patent system has facilitated transfer of technology and local manufacturing of medicines in developing countries and LDCs.
Pakistan supports the GRULAC proposal regarding Revision of the 1979 WIPO Model Law for Developing Countries on Inventions contained in Document SCP/22/5. In line with the Development Agenda recommendations for WIPO’s technical and legislative assistance to be development oriented this is important to ensure that developing countries are able to fully utilize available flexibilities in an updated manner.
My delegation looks forward to a productive session.
I thank you